Correction to: Blood Cancer Journal (2014) 4, e182; doi:10.1038/bcj.2014.1; published online 21 February 2014
Since the publication of this article, the authors have identified an error concerning one of the author affiliation addresses. KC Anderson was incorrectly affiliated to the following address: ‘Merck & Co. Inc., Whitehouse Station, NJ, USA’. The correct address details are shown here.
The article has also been rectified, and now carries the correct information.
The Authors would like to apologise for any inconvenience this may have caused.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at 10.1038/bcj.2014.1
Rights and permissions
About this article
Cite this article
Siegel, D., Richardson, P., Dimopoulos, M. et al. Erratum: Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood Cancer Journal 4, e202 (2014). https://doi.org/10.1038/bcj.2014.23
Published:
Issue Date:
DOI: https://doi.org/10.1038/bcj.2014.23
This article is cited by
-
Posttransplant maintenance therapy in multiple myeloma: the changing landscape
Blood Cancer Journal (2017)
-
Novel agents in the treatment of multiple myeloma: a review about the future
Journal of Hematology & Oncology (2016)
-
Treatment-related symptom management in patients with multiple myeloma: a review
Supportive Care in Cancer (2015)
